

Received:

15 December 2018

Revised:

25 February 2019

Accepted:

28 February 2019

Cite as: Samir Chtita, Mounir Ghamali, Abdellah Ousaa, Adnane Aouidate, Assia Belhassan, Abdelali Idrissi Taourati, Vijay Hariram Masand, Mohammed Bouachrine, Tahar Lakhli. QSAR study of anti-Human African Trypanosomiasis activity for 2-phenylimidazopyridines derivatives using DFT and Lipinski's descriptors. Heliyon 5 (2019) e01304. doi: 10.1016/j.heliyon.2019.e01304



QSAR study of anti-Human African Trypanosomiasis activity for 2-phenylimidazopyridines derivatives using DFT and Lipinski's descriptors

Samir Chtita^{a,b,*}, Mounir Ghamali^b, Abdellah Ousaa^b, Adnane Aouidate^b, Assia Belhassan^{b,d}, Abdelali Idrissi Taourati^b, Vijay Hariram Masand^c, Mohammed Bouachrine^{b,d}, Tahar Lakhli^b

^a Laboratory Physical Chemistry of Materials, Faculty of Sciences Ben M'Sik, University Hassan II, Casablanca, Morocco

^b MCNSL, Department of Chemistry, Faculty of Sciences, University Moulay Ismail, Meknes, Morocco

^c Department of Chemistry, Vidya Bharati College, Camp. Amravati, Maharashtra, India

^d MEM, Department of Chemistry, High School of Technology, University Moulay Ismail, Meknes, Morocco

* Corresponding author.

E-mail address: samirchtita@gmail.com (S. Chtita).

Abstract

The quantitative structure-activity relationship (QSAR) of sixty 2-phenylimidazopyridines derivatives with anti-Human African Trypanosomiasis (anti-HAT) activity has been studied by using the density functional theory (DFT) and statistical methods. Becke's three-parameter hybrid method and the Lee-Yang-Parr B3LYP functional employing 6–31G(d) basis set are used to calculate quantum chemical descriptors using Gaussian 03W software, and the five Lipinski's parameters were calculated using ChemOffice software.

In order to obtain robust and reliable QSAR model, the original dataset was randomly divided into training and prediction sets comprising 48 and 12 compounds, respectively. An optimal model for the training set with significant

statistical quality was established. The same model was further applied to predict pEC₅₀ values of the 12 compounds in the test set, further showing that this QSAR model has high predictive ability. It is very interesting to find that the anti-HAT of these compounds appear to be mainly governed by four factors, i.e., the number of H-bond donors, the lowest unoccupied molecular orbital energy, the molecular weight and the octanol/water partition coefficient. Here the possible action mechanism of these compounds was analysed and discussed, in particular, important structural requirements for great anti-HAT activity will be by increasing molecular size and substitute the 2-phenylimidazopyridines derivatives with polar, ionic, stronger accepting electron ability group and heteroatoms attached to one or more hydrogen atoms. Based on this proposed QSAR model, some new compounds with higher anti-HAT activities have been theoretically designed. Such results can offer useful theoretical references for future experimental works.

Keyword: Pharmaceutical chemistry

1. Introduction

Human African Trypanosomiasis (HAT) or African sleeping sickness is one of the infectious diseases grouped under the term Neglected Tropical Diseases, which inflict a devastating effect on the health and economy of nearly 150 countries [1, 2, 3]. In Africa, the number of cases has dropped drastically; however, approximately 3,000 new infections of both East and West African Trypanosomiasis have been reported by the World Health Organization in 2015 [4]. HAT-affected 60 zones covering an area of about 8 million square kilometers between 14° north latitude and 20° south latitude [5]. Most cases of HAT are caused by the protozoans *Trypanosoma brucei gambiense* and *Trypanosoma brucei rhodesiense*, which are transmitted to humans through the bite of tsetse flies in rural areas of sub-Saharan Africa.

The disease has two stages: the initial stage is characterized by the spread of the parasite in the blood and the lymphatic system; and in the second stage, the parasite crosses the *blood–brain barrier* (BBB) in which the parasites spread into the central nervous system [6, 7, 8]. Symptoms of this later stage include sleep disturbance, cognitive dysfunction, coma, and death.

Current treatment for the treatment of HAT includes *suramin*, *pentamidine*, *melarsoprol*, *eflornithine*, or a combination of *nifurtimox* and *eflornithine* (Chemical structures of existing anti-HAT medicines are shown in Fig. 1) [6, 9, 10, 11]. These existing medicines are insufficient, antiquated, toxic, prone to resistance, and require parenteral administration [12, 13, 14, 15, 16, 17]. A new drug, effective for late stage disease that is nontoxic and orally administered, is urgently needed.




Fig. 1. Chemical structures of existing anti-HAT medicines.

In order to open a new way in anti-HAT drug research, a series of sixty 2-phenylimidazopyridine derivatives were synthesized and studied for their anti-HAT activities by *Tatipaka et al.* [18] to design a better analogue, with rich metabolic stability in liver microsomes, of substituted oxazolopyridine identified as an attractive lead due to good whole-cell activity on *Trypanosoma brucei rhodesiense*, no cytotoxicity on mammalian cell lines, acceptable exposure in the central nervous system, and satisfactory aqueous solubility.

The main focus of the present study is to develop a QSAR model able to correlate the structural features of the 2-phenylimidazopyridine derivatives with their anti-HAT activities.

In general, the QSAR models are based on the assumption that the activity of a certain chemical compound related to its structure through a certain mathematical algorithm. This relationship can be used in the prediction, interpretation, and assessment of new compounds with desired activities, reducing and rationalizing time, efforts, and cost of synthesis as well as new product development. The basic assumption to drive a QSAR model is presented in the form of a mathematical function associating the chemical properties to the effect (activity). Therefore, the effect is like the function “*f*” of the chemical properties “*x*”: $y = f(x)$. To find this algorithm, a number of chemical compounds with known values of the studied effect (*y*) are considered. For each chemical compound, myriad numbers of parameters (called as chemical descriptors) are calculated. Then, QSAR models are built that provides a quite accurate value, similar to the real experimental value. The final step is to check if the obtained QSAR models are able to predict the activity values for other chemicals not used to build up the model (external validation). Indeed, it is very important to generate a model which worked not only for the chemical

substances used within the training set but also for other similar chemicals. Consequently, the challenge is to define the correct statistical properties of the model [19, 20].

The significance and novelty of findings presented in this work are reflected from the fact that we have used quantum chemistry descriptors which describes electron properties of congeneric structures used in this study, and we have used the five Lipinski's descriptors to describes compounds could be potential orally administered drugs. The use of density functional theory (DFT) is justified for the reason that some comparative QSAR studies have shown that the descriptors calculated using the DFT method can improve the accuracy of the results and lead to more reliable QSARs [19].

A flow chart for the development of the QSAR model along with the various validation methods used in this work is demonstrated in Fig. 2.

2. Materials and method

2.1. Selection of dataset and generation of molecular descriptors

2.1.1. Data set

In this stage, the data set of the anti-HAT activities of sixty 2-phenylimidazopyridines derivatives were collected from the literature [18, 35]. The molecular structures of the studied molecules with their activity are presented in Fig. 3 and Table 1. All experimental activity values EC_{50} (of compound required to inhibit growth by 50%) were converted to the negative logarithm of EC_{50} ($pEC_{50} = -\log_{10}(EC_{50})$).




Fig. 2. Flow chart of the methodology used in this work.




Fig. 3. Chemical structures of the studied compounds skeletons.

2.1.2. Molecular descriptors

Electronic and Lipinski's parameters were calculated using *Gaussian 03W* and *ChemOffice* programs, respectively [21, 22], to predict the correlation between these descriptors of the studied molecules with their anti-HAT activities and to develop linear model. Table 2 shows the used descriptors in this study.

2.2. Data set

In this stage, linear QSAR model was developed and evaluated to predict the studied activities of compounds. The descendent multiple linear regression (MLR) analysis available in *XLSTAT* software [23], based on the elimination of aberrant descriptors (one by one) until a valid model (including the critical probability: $p\text{-value} < 0.05$ for descriptors and for the model), was employed to find a linear model of the activity of interest, which takes the form below:

$$Y = a_0 + \sum_{i=1}^n a_i x_i$$

Where:

Y: the studied activity, which is, the dependent variable; a_0 : the intercept of the equation; x_i : the molecular descriptors; a_i : the coefficients of those descriptors.

This method is one of the most popular methods of QSAR due to its simplicity in operation, reproducibility and ability to allow easy interpretation of the features used. The important advantage of the linear regression analysis is its transparent nature, therefore, the algorithm is accessible and predictions can be made easily [20].

In order to propose models and to evaluate quantitatively the physicochemical effects of the substituents on the studied activities, we submitted the data matrix constituted obviously from the used variables (descriptors) corresponding to the dataset molecules to a MLR. We use the coefficients R^2 , MSE and $p\text{-value}$ to select the best regression performance [24]. Where:

1. The R-squared (R^2) also called the coefficient of determination, which is the proportion of variance (%) in the dependent variable that can be explained by the independent variable. Since R^2 value is adopted in various research disciplines, there is no standard guideline to determine the level of predictive acceptance.

Table 1. Chemical structures and anti-HAT activities of studied compounds.

	<i>N</i> ^o	<i>R</i> ₁	<i>R</i> ₂	<i>R</i> ₃	<i>pEC</i> ₅₀
(A)	1	H	Cl		6.658
	2	H	F		6.921
	3	H	CH ₃		6.367
	4	H	CN		6.398
	5	Br	F		6.638
	6	CN	F		6.420
	7	Phenyl	F		7.398
	8 (*)	4-fluorophenyl	F		7.301
	9	3-chlorophenyl	F		7.301
	10	4-MeO-phenyl	F		6.770
	11 (*)	4-phenylphenyl	F		6.377
(B)	12	5-methylfuran-2-carbonyl	H	F	6.699
	13	3-methylfuran-2-carbonyl	H	F	7.000
	14	3-furanoyl	H	F	6.824
	15	benzoyl	H	Cl	5.149
	16	oxazole-5-carbonyl	H	F	5.721
	17	2-thiophenyl	H	Cl	5.824
	18 (*)	3-pyridinecarbonyl	H	F	5.155
	19	pyrazine-2-carbonyl	H	F	6.046
	20 (*)	N-methylpyrrole-2-carbonyl	H	F	5.959
	21 (*)	methylsulfonyl	H	Cl	5.215
	22	2-furancarbothiyl	H	F	6.387
	23	2-furanoyl	2-acetyl	F	6.301
	24	2-furanoyl	2-furanoyl	F	6.921
	25	benzyl	Benzyl	F	5.959
	26	methylcarbamoyl	H	F	5.420
	27	isopropylcarbamoyl	H	Cl	6.000
	28	phenylcarbamoyl	H	Cl	4.921
	29	dimethylcarbamoyl	H	Cl	6.398
	30	1-pyrrolidinoyl	H	Cl	7.046
	31	1-piperidinoyl	H	Cl	5.721
(C)	32	2-furanyl	H		6.699
	33 (*)	2-furanyl	Cl		7.155
	34	2-furanyl	F		6.699
	35	2-furanyl	5-Cl		5.000
	36	2-furanyl	7-Cl		6.921

(continued on next page)

Table 1. (Continued)

N°	R_1	R_2	R_3	pEC_{50}
37	N-pyrrolidinyl	Cl		7.301
38	N-pyrrolidinyl	phenyl		8.699
39	N-pyrrolidinyl	3-methoxyphenyl		8.000
40 (*)	N-pyrrolidinyl	2-methoxyphenyl		8.301
41	N-pyrrolidinyl	3-chlorophenyl		8.699
42	N-pyrrolidinyl	2-chlorophenyl		8.301
43	N-pyrrolidinyl	3-acetylphenyl		8.523
44	N-pyrrolidinyl	3-methylphenyl		8.699
45 (*)	N-pyrrolidinyl	3-trifluoromethoxyphenyl		7.523
46 (*)	N-pyrrolidinyl	3-methyl-4-fluorophenyl		7.699
47 (*)	N-pyrrolidinyl	3-NH ₂ -phenyl		8.000
48	N-pyrrolidinyl	3-furanyl		8.398
49	N-pyrrolidinyl	3-thiophenyl		8.699
50	N-pyrrolidinyl	2-thiophenyl		8.398
51	N-pyrrolidinyl	3-pyridyl		8.301
52 (*)	N-pyrrolidinyl	5-(2-chloropyridyl)		8.000
53	N-pyrrolidinyl	4-(2-chloropyridyl)		8.398
54	N-pyrrolidinyl	5-(3-methylpyridyl)		8.000
55	N-pyrrolidinyl	5-(2-methoxypyridyl)		8.301
56	N-pyrrolidinyl	5-(3-pyrrolidino)		7.699
57	N-pyrrolidinyl	5-(3-chloropyrimidinyl)		8.301
58 (*)	N-pyrrolidinyl	5-pyrimidinyl		7.523
59	N-pyrrolidinyl	5-(2-methoxypyrimidinyl)		7.222
60	N-pyrrolidinyl	5-(2-chloropyrimidinyl)		7.398

(*): Test set compounds. $pEC_{50} = -\log_{10} (EC_{50})$.

Henseler et al. [25] and Hair et al [26, 27] proposed a rule of thumb for acceptable R^2 with 0.75, 0.50, and 0.25 are described as substantial, moderate and weak respectively.

Hence, Zikmund et al. and Moore et al. proposed other rule of thumb for interpreting the strength of a relationship based on its R-squared value (use the absolute value of the R-squared value to make all values positive) [28, 29]:

- If R-squared value $R^2 < 0.3$ this value is generally considered a none or very weak effect size,
- If R-squared value $0.3 < R^2 < 0.5$ this value is generally considered a weak or low effect size,
- If R-squared value $0.5 < R^2 < 0.7$ this value is generally considered a Moderate effect size,

Table 2. Values of parameters calculated for the studied compounds.

N°	E	μ	E _{HOMO}	E _{LUMO}	MW	NHA	NHD	NRB	log P
1	-40922.340	7.904	-6.113	-1.901	340.049	6	2	3	3.843
2	-31116.982	7.495	-6.062	-1.826	324.079	7	2	3	3.243
3	-29486.806	6.018	-5.939	-1.713	320.104	6	2	3	3.989
4	-30936.391	11.034	-6.432	-2.241	331.083	6	2	3	3.518
5	-101076.674	6.975	-6.153	-2.043	401.990	7	2	3	4.182
6	-33626.856	7.421	-6.348	-2.466	349.074	8	2	4	2.921
7	-37404.050	7.610	-5.949	-1.884	400.110	7	2	4	5.131
8	-40104.179	6.960	-5.983	-1.936	418.101	8	2	4	5.373
9	-49909.639	8.257	-6.067	-2.012	434.071	7	2	4	5.854
10	-40520.225	7.508	-5.686	-1.802	430.121	8	2	5	5.236
11	-43691.129	7.708	-5.839	-1.910	476.142	7	2	5	7.019
12	-32186.636	5.317	-6.146	-1.987	339.102	6	2	3	3.796
13	-32186.624	5.231	-6.245	-2.003	337.086	6	1	7	2.724
14	-31116.792	6.390	-6.030	-1.870	324.079	7	2	3	3.243
15	-40982.768	7.474	-6.166	-1.924	350.070	5	2	3	4.667
16	-31553.426	5.145	-6.267	-1.966	327.090	8	3	3	2.793
17	-49770.221	7.034	-5.890	-2.125	366.047	4	2	2	4.727
18	-31613.730	5.406	-6.222	-1.915	335.095	7	2	3	3.314
19	-32050.206	6.769	-6.173	-2.301	336.090	8	2	3	2.881
20	-31646.188	6.852	-5.952	-1.909	336.102	6	1	4	2.903
21	-47607.896	5.054	-6.359	-2.028	323.013	5	1	3	1.935
22	-39904.311	7.314	-5.869	-2.111	340.056	6	2	3	3.303
23	-35270.067	8.211	-6.247	-1.968	365.081	7	0	5	2.329
24	-40426.686	5.467	-6.361	-1.970	418.084	9	1	5	4.774
25	-36519.016	6.360	-5.499	-1.613	410.167	6	1	5	6.650
26	-27466.414	8.042	-5.960	-1.761	286.087	5	2	4	1.896
27	-39411.369	8.621	-5.993	-1.822	330.088	4	2	5	3.053
28	-42489.155	1.786	-5.891	-1.916	365.081	5	3	4	4.707
29	-38341.359	8.507	-5.957	-1.812	316.073	4	1	4	2.091
30	-40448.111	9.131	-5.884	-1.777	343.097	5	2	3	3.828
31	-41517.874	8.542	-5.927	-1.804	357.112	5	2	3	4.387
32	-30576.266	3.031	-6.117	-1.602	323.095	7	3	3	3.625
33	-43081.767	4.761	-6.292	-1.885	357.056	7	3	3	4.483
34	-33276.260	4.502	-6.216	-1.786	341.086	8	3	3	4.002
35	-43081.927	4.900	-6.281	-1.815	357.056	7	3	3	4.483
36	-43081.878	1.860	-6.339	-1.780	357.056	7	3	3	4.483
37	-42608.017	4.941	-6.020	-1.827	360.103	6	3	3	3.179
38	-36389.529	4.940	-5.774	-1.680	402.174	6	3	4	4.209

(continued on next page)

Table 2. (Continued)

N°	E	μ	E _{HOMO}	E _{LUMO}	MW	NHA	NHD	NRB	log P
39	-39505.695	4.609	-5.694	-1.673	432.184	7	3	5	4.236
40	-39505.605	4.478	-5.577	-1.544	432.184	7	3	5	3.676
41	-48895.128	5.536	-5.913	-1.803	436.135	6	3	4	4.951
42	-48895.018	5.269	-5.881	-1.704	436.135	6	3	4	4.701
43	-40543.039	6.462	-5.862	-1.776	444.184	7	3	5	3.749
44	-37459.374	4.947	-5.736	-1.655	416.189	6	3	4	4.708
45	-47606.991	5.648	-5.912	-1.805	486.156	10	3	6	5.345
46	-40159.542	4.670	-5.759	-1.699	434.180	7	3	4	4.880
47	-37895.697	6.101	-5.482	-1.614	417.184	7	4	4	3.162
48	-36328.934	4.630	-5.691	-1.680	392.153	7	3	4	3.385
49	-45117.304	5.511	-5.726	-1.688	408.130	6	3	4	5.213
50	-45117.314	5.785	-5.634	-1.763	408.130	6	3	4	5.423
51	-36825.916	3.244	-5.931	-1.806	403.169	7	3	4	4.245
52	-49331.575	4.023	-6.029	-1.933	437.130	7	3	4	5.010
53	-49331.591	4.764	-6.111	-2.046	437.130	7	3	4	5.010
54	-37895.779	2.889	-5.899	-1.776	417.184	7	3	4	4.833
55	-39942.234	2.459	-5.734	-1.714	433.179	8	3	5	5.154
56	-42577.963	2.351	-5.259	-1.654	472.227	8	3	5	5.112
57	-49331.478	4.961	-6.042	-1.940	437.130	7	3	4	5.010
58	-37262.327	5.486	-6.061	-1.960	404.164	8	3	4	3.338
59	-40378.895	3.634	-5.918	-1.830	434.175	9	3	5	4.373
60	-49767.937	6.555	-6.138	-2.084	438.125	8	3	4	4.065

- If R-squared value $R^2 > 0.7$ this value is generally considered strong effect size.

2. The mean square error (MSE): measure the average squared difference between the predicted and experimental activities values.

$$MSE = \frac{1}{N} \sum_{i=1}^N (y_i^{pred} - y_i^{obs})^2$$

N: The number of data points

y_i^{pred} : The predicted (calculated by the model) value for data point i.

y_i^{obs} : The actual (observed) value for data point i.

The MSE is always strictly positive, and a good model will be with MSE values closer to zero, i.e. the good model will be with minimize the sum of the squared difference between the true and estimated values [30].

3. *P-value*: the significance level, which gives an indication of the probability that a QSAR is a significant occurrence.

In order to assess the significance of the models and its accurate prediction ability for new compounds:

4. The variance inflation factor VIF [31] to detect the absence of the multicollinearity between descriptors was used; models with descriptors correlated with each other are not significant. The VIF was defined as $1/(1-R^2)$, where R is the coefficient of correlation between one descriptor and all other descriptors in model. A VIF value greater than 5.0 indicates that the model is unstable; a value between 1.0 and 4.0 indicates that the model is acceptable [32].
5. In addition, an internal validation procedure (leave-one-out cross validation) was employed, in which one compound is removed and the rebuilt model with the remaining molecules is used to predict the response of the eliminated compound. This one is then returned and a second is removed, and the cycle is repeated, and so on until all compounds have been removed one by one, and an overall correlation coefficient R_{cv} is computed [33]. A model is considered acceptable when the value of R_{cv}^2 exceeds 0.6 [27, 32].
6. After the model is built, an external prediction is necessary. This one remains the only way to determine both the generalizability of QSAR model for new chemicals and the true predictive power of the models. In this external validation, the obtained model was used to predict the activities of a test set comprising compounds that are similar to though not used in the training set. This is usually performed by splitting a data set into a training set a test set, typically in a 1:5 ratio [34].
7. A model is valid only within its training domain and new molecules must be considered as belonging to the domain before the model is applied (OECD Principle 3 [35]). Without applicability domain (AD), each model can predict the activity of any compound, even with a completely different structure from those included in the study. Therefore, the AD is a tool to find out compounds that are outside of the built QSAR model and it detects outliers present in the training set compounds. There are several methods for defining the applicability domain (AD) of QSAR models [36], but the most common one is determining the leverage values h_i ($h_i = x_i^t (X^t X)^{-1} x_i$ ($i = 1, 2, \dots, n$)) for each compound, where: x_i : the descriptor row-vector of query compound, X : the $n*(k-1)$ matrix of k model descriptor values for n training set compounds and the superscript t refers to the transpose of matrix/vector [37]. In this study, we use the *Williams* plot; in this plot, the applicability domain is established inside a squared area within standard deviation $\pm x$ (in this study $x = 2.5$; “three sigma rule” [38]) and a leverage threshold h^* ($h^* = 2.5*(k+1)/n$) [39]. Where: n is the number of training set compounds, k is the number of model descriptors. The leverage (h) greater than the warning leverage (h^*) suggested that the compound was very influential on the model [40].
8. Further, the y-randomization approach was performed to ensure the robustness of a predictive model. Often, it is used along with the cross-validation. It consists of

repeating the calculation procedure with randomized activities and subsequent probability assessment of the resultant statistics. The dependent variable vector is randomly shuffled and a new predictive model is developed using the original independent variable matrix. The new predictive models (after several repetitions) are expected to have low R^2 and R_{cv}^2 values. If the opposite happens, then an acceptable model cannot be obtained for the specific modelling method and data [41]. Another parameter, cRp^2 is also calculated which should be more than 0.5 for passing this test: $cRp^2 = R^* \sqrt{(R^2 - (Average\ Rr)^2)}$. Where: Average Rr = average 'R' of random models [42].

3. Results and discussions

3.1. Molecular descriptors

From the results of the density functional theory DFT (B3LYP/6-31G (d)) calculations, following quantum chemistry descriptors were obtained for building the model: total energy E , dipole moment μ , highest occupied molecular orbital energy E_{HOMO} and lowest unoccupied molecular orbital energy E_{LUMO} .

The five Lipinski's parameters calculated are: molecular weight MW , number of H-bond acceptors NHA , number of H-bond donors NHD , number of rotatable bonds NRB and octanol/water partition coefficient $\log P$ (Table 2).

3.2. Multiple linear regression (MLR)

The QSAR analysis was performed using calculated molecular descriptors and the experimental values of the anti-HAT activities for the forty-eight 2-phenylimidazopyridines derivatives (effect). The established MLR model is represented by the following equation along with the values of the statistical parameters:

$$pEC_{50} = 3.036 + 1.196 E_{LUMO} + 0.019 MW + 0.301 NHD - 0.398 \log P \quad (1)$$

$$R^2 = 0.598; R = 0.773; MSE = 0.508; p\text{-value} < 10^{-4}$$

The values of calculated activities from Eq. (1) have been presented in Table 3 and the correlations of calculated and observed activities values are illustrated in Fig. 4.

The p -value is lower than 0.0001, it means that we would be taking a lower than 0.01% risk in assuming that the null hypothesis (no effect of the explanatory variables) is wrong. The equation has statistical significance. Therefore, we can conclude with confidence that the selected variables do bring a significant amount of information.

The value of R^2 and the MSE indicate that the proposed model is predictive and reliable.

Table 3. Observed and predicted activities using the MLR models for the training set.

N°	pEC ₅₀	MLR	Residues	N	pEC ₅₀	MLR	Residues
1	6.658	6.250	0.408	30	7.046	6.463	0.584
2	6.921	6.278	0.643	31	5.721	6.472	-0.751
3	6.367	6.041	0.326	32	6.699	6.676	0.024
4	6.398	5.804	0.595	34	6.699	6.645	0.054
5	6.638	7.115	-0.477	35	5.000	6.720	-1.720
6	6.420	6.112	0.308	36	6.921	6.762	0.159
7	7.398	6.891	0.507	37	7.301	7.283	0.019
9	7.301	7.091	0.210	38	8.699	7.842	0.857
10	6.770	7.514	-0.744	39	8.000	8.406	-0.406
12	6.699	6.148	0.551	41	8.699	8.040	0.660
13	7.000	6.217	0.783	42	8.301	8.258	0.043
14	6.824	6.225	0.599	43	8.523	8.703	-0.180
15	5.149	6.084	-0.935	44	8.699	7.938	0.761
16	5.721	6.647	-0.926	48	8.398	7.981	0.417
17	5.824	6.121	-0.297	49	8.699	7.545	1.154
19	6.046	6.081	-0.035	50	8.398	7.371	1.027
22	6.387	6.214	0.173	51	8.301	7.695	0.606
23	6.301	6.643	-0.342	53	8.398	7.744	0.654
24	6.921	6.968	-0.047	54	8.000	7.762	0.238
25	5.959	6.499	-0.540	55	8.301	8.010	0.291
26	5.420	6.174	-0.754	56	7.699	8.835	-1.136
27	6.000	6.472	-0.472	57	8.301	7.872	0.429
28	4.921	6.661	-1.740	59	7.222	8.201	-0.979
29	6.398	6.301	0.097	60	7.398	8.094	-0.696

The VIF values of all four descriptors in MLR model are smaller than 4.0 (VIF = 1.173, 2.170, 1.270 and 2.094 for E_{LUMO}, MW, NHD and log P, respectively) indicating that there is no collinearity among the selected descriptors and the resulting model has good stability.

The obtained model was validated internally by the *leave-one-out* cross validation technique, the cross-validation coefficient R²_{cv} for the model was determined based on the predictive ability of the model. The value of R²_{cv} is higher than 0.5 (R²_{cv} = 0.509), it indicates the better predictively of the model.

True predictive power of this model is to test their ability to predict perfectly the pEC₅₀ of compounds from an external test set (compounds that were not used for the developed model), the pEC₅₀ of the remained set of 12 compounds are deduced from the quantitative model proposed with the compounds used in training set by




Fig. 4. Correlations of observed and predicted activities (training set in blue and test set in red) values calculated using MLR models.

MLR. This model will be able to predict the activities of test set molecules in agreement with the experimentally determined value. The observed and calculated pEC_{50} values are given in Table 4. The predictive capacity of the models that was judged, the higher value of R^2_{test} ($R^2_{test} = 0.700$) indicate the improved predictivity of the model.

In the Eq. (1), the number of H-bond donors NHD, the lowest unoccupied molecular orbital energy E_{LUMO} and the molecular weight MW influence positively the

Table 4. Chemical descriptors, observed and MLR predicted activities for the test set.

Test Set					pEC_{50}	
N°	E_{HOMO}	MW	NHD	logP	Obs.	MLR
8	-1.936	418.101	2	5.373	7.301	7.072
11	-1.910	476.142	2	7.019	6.377	7.543
18	-1.915	335.095	2	3.314	5.155	6.351
20	-1.909	336.102	1	2.903	5.959	6.239
21	-2.028	323.013	1	1.935	5.215	6.235
33	-1.885	357.056	3	4.483	7.155	6.636
40	-1.544	432.184	3	3.676	8.301	8.783
45	-1.805	486.156	3	5.345	7.523	8.824
46	-1.699	434.180	3	4.880	7.699	8.156
47	-1.614	417.184	4	3.162	8.000	8.922
52	-1.933	437.130	3	5.010	8.000	7.880
58	-1.960	404.164	3	3.338	7.523	7.892

activities and the octanol/water partition coefficient log P influence negatively the activities.

By definition:

- Molecular weight MW is the sum of the masses of all the atoms in the molecular formula of the molecule. This descriptor has been used as a descriptor in systems such as transport studies where diffusion is the mode of operation. It is an important variable in QSAR studies pertaining to cross resistance of various drugs in multidrug resistant cell lines [43, 44]. For orally delivered drugs, the molecular weight must be less than or equal to 500 Daltons [45].
- Partition coefficient octanol-water (Log P) is the ratio of concentrations of a substance in a mixture of two solvents, octanol and water. Both solvents are immiscible and therefore form two phases [46].

$$\text{LogP} = \log \frac{[\text{Octanol}]}{[\text{Water}]}$$

The LogP is the most useful parameter for the characterization of hydrophobicity (and polarity) of compounds [47]. It is an important variable in QSAR studies because the distribution of chemicals between fatty and aqueous phases of a biological system could totally account for the variation in activities [48]. For orally delivered drugs, the partition coefficient octanol-water must be less than 5 [45].

- The number of H-bond Donors NHD is a crucial descriptor in the description of diverse processes occurring in condensed media such as dissolving, partitioning, solubilisation, etc. Drug action and bioavailability critically depends on aqueous solubility, blood-tissue distribution, and specifically on hydrogen binding to receptor active sites and transport proteins [49]. For orally delivered drugs, the hydrogen bond donors must be less than 5 [45].
- The lowest unoccupied molecular orbital energy, E_{LUMO} : HOMO and LUMO refer to highest occupied molecular orbital and lowest unoccupied molecular orbital. According to the frontier orbital theory, the nucleophilic attack occurs by electron flow from the HOMO of the nucleophile into the LUMO of the electrophile. In stable molecules, occupied electrons always reside into orbitals with negative energies and unoccupied orbitals have positive energies. The energies of HOMO and LUMO are related to the reactivity of the molecule: molecules with electrons at accessible (near-zero) HOMO levels tend to be good nucleophiles because it does not cost much to donate these electrons toward making a new bond. Similarly, molecules with lower LUMO energies tend to be good electrophiles because it does not cost much to place an electron into such an orbital [50, 51].

Comparing the importance of each descriptor on pEC_{50} of 2-phenylimidazopyridines, one must know the standardized coefficient or the *t-test* values of them in the model

equation. The bigger the absolute value of the *t*-test value is, the greater the influence of the descriptor is. The *t*-test values for our model descriptors are 1.928, 5.714, 1.883 and -2.639 for E_{LUMO} , MW, NHD, and logP, respectively. This means that the *t*-test value of logP is larger than that of other three descriptors, which indicate that in this model, the influence of MW on activity is stronger than that of the others.

Consequently, if we want to increase the value of the activity, we will:

- Decrease the logP (with negative sign in the model) value, for which we must substitute the 2-phenylimidazopyridines derivatives for hydrophilic ("water-loving") substituents. This means that a substitution with a polar and ionic group (such as: -OH, -COOH, -NH₂) may lead to high activity values.
- Increase the E_{LUMO} value, for which we suggests the substitution of the 2-phenylimidazopyridines derivatives with a stronger accepting electron ability group, positively charged or neutral species having vacant orbitals that are attracted to an electron rich centre (such as ROX, BH, -NO₂).
- Increase the NHD (with positive sign in the model) value, for which substituting the 2-phenylimidazopyridines derivatives by heteroatom attached to one or more hydrogen atoms.
- Increase the MW value, for which increasing the molecular size.

In the conclusion, these results illustrates that to increase the anti-HAT, we will increase the molecular size and substitute the 2-phenylimidazopyridines derivatives with polar, ionic, stronger accepting electron ability group and heteroatoms attached to one or more hydrogen atoms.

This study is in agreement with the conclusions of a previous QSAR studies [52] which revealed the importance the presence of five membered rings, especially the pyrrolidine ring, is beneficial for the HAT activity of the present series of molecules; and the interesting pattern of H-bond donor/acceptor nitrogen atoms in attaining various tautomeric forms, thereby, providing additional flexibility to the molecules to acquire bioactive tautomeric form(s) while interacting with the target receptor.

Further, before performing the external validation of a model, it is very important to check for the presence of systematic error that violates the basic assumptions of the least squares regression model. If high systematic error (bias) is present in the model, then such model should be discarded and performing any external validation test is of no use on such biased model. Xternal Validation Plus is a tool that checks the presence of systematic errors in the model and further computes all the required external validation parameters, while judging the performance of actual prediction quality of a QSAR model based on recently proposed MAE-based criteria [53];

Table 5. Output file summarize the information including all the external validation parameters that are required to judge the performance of prediction quality of the MLR model.

User Input File Info.	File Name	Sample_TestSet.xlsx
Model biasness test	nPE/nNE	0.3333
	nNE/nPE	3.0000
	MPE/MNE	0.3620
	MNE/MPE	2.7623
	AAE - AE	0.1447
	R2 (Residuals; serial correlation)	0.0421
	R2 (Residuals and Yobs values)	0.1383
Classical Metrics (for 100% data)	R ² Test (100% data)	0.6997
	R ₀ ² Test (100% data)	0.6978
	R ₀ ^{2'} Test (100% data)	0.6123
	Q2F1 (100% data)	0.4622
	Q2F2 (100% data)	0.4291
	Scaled Avg.Rm2 (100% data)	0.5094
	Scaled DeltaRm2 (100% data)	0.2532
	CCC(100% data)	0.7351
	R2Test (95% data)	0.7330
	R02Test (95% data)	0.7321
Classical Metric (after removing 5% data with high residuals)	R0'2Test (95% data)	0.4763
	Q2F1 (95% data)	0.5674
	Q2F2 (95% data)	0.5506
	ScaledAvgRm2 (95% data)	0.5028
	ScaledDeltaRm2 (95% data)	0.2536
	CCC(95% data)	0.7703
Error-based metrics (for 100% data)	RMSEP (100% data)	0.7834
	SD (100% data)	0.4210
	SE (100% data)	0.1215
	MAE (100% data)	0.6718
Error-based metric (after removing 5% data with high residuals)	RMSEP (95% data)	0.7181
	SD (95% data)	0.3896
	SE (95% data)	0.1175
	MAE (95% data)	0.6145
	MAE+3*SD (95% data)	1.7834
	NCompTest	12.0000
Number of test set compounds.	Train range	7.8195

(continued on next page)

Table 5. (Continued)

User Input File Info.	File Name	Sample_TestSet.xlsx
Range and Mean (train and test)	TrainYMean	6.7604
	Test range	3.1460
	TestYMean	7.0173
Distribution of observed response values of Test set around Test mean (in %)	%Y (± 0.5)TestMean	16.6667
	%Y (± 1.0)TestMean	66.6667
	%Y (± 1.5)TestMean	83.3333
	%Y (± 2.0)TestMean	100.0000
Distribution of observed response values of Test set around Train mean (in %)	%Y (± 0.5)TrainMean	16.6667
	%Y (± 1.0)TrainMean	58.3333
	%Y (± 1.5)TrainMean	75.0000
	%Y (± 2.0)TrainMean	100.0000
Distribution of prediction errors (in %)	%NComp>(0.1*TR)	41.6667
	%NComp>(0.15*TR)	16.6667
	%NComp>(0.2*TR)	0.0000
	%NComp>(0.25*TR)	0.0000
Threshold values utilized to judge the model predictions	(0.1*TrainingSetRange)	0.7820
	(0.15*TrainingSetRange)	1.1729
	(0.2*TrainingSetRange)	1.5639
	(0.25*TrainingSetRange)	1.9549
RESULT (MAE-based criteria applied on 95% data)	Prediction Quality	MODERATE

Xternal Validation Plus indicates the absence of systematic errors in the model and a moderate performance of prediction quality of a QSAR model based on proposed MAE-based criteria (Table 5).

In the next step, all calculations were repeated with randomized activities of the training set compounds as well to evaluate model robustness (y-randomization test). In the present case, 100 random trials were run for the MLR model. None of the random trials could match the original model (Table 6). The standalone QSAR-tools (“Programs”) available online at <http://dtclab.webs.com/software-tools> and http://teqip.jdvu.ac.in/QSAR_Tools/ (“Websites”) was employed in the y-randomization.

The average value of R , R^2 and R_{CV}^2 are 0.282, 0.087 and -0.155 respectively, the cRp^2 value equal a 0.557 (more than 0.5), and all the new QSAR models having significantly low R^2 and R_{CV}^2 values for the 100 trials, which confirm that the developed QSAR models are robust.

The applicability domain (AD) of the MLR models was evaluated by leverage analysis expressed as *Williams* plot (Fig. 5), in which the standardized residuals and the

Table 6. Y-randomization test results for MLR models.

Random	R	R ²	R ² _{CV}	Random	R	R ²	R ² _{CV}	Random	R	R ²	R ² _{CV}	Random	R	R ²	R ² _{CV}
1	0,119	0,014	-0,319	26	0,141	0,020	-0,246	51	0,212	0,045	-0,230	76	0,219	0,048	-0,185
2	0,382	0,146	-0,049	27	0,398	0,158	-0,122	52	0,278	0,077	-0,113	77	0,202	0,041	-0,222
3	0,419	0,176	0,013	28	0,242	0,059	-0,270	53	0,349	0,122	-0,073	78	0,249	0,062	-0,248
4	0,212	0,045	-0,159	29	0,388	0,150	-0,072	54	0,251	0,063	-0,235	79	0,341	0,116	-0,112
5	0,196	0,039	-0,177	30	0,133	0,018	-0,224	55	0,354	0,125	-0,136	80	0,154	0,024	-0,192
6	0,368	0,135	-0,148	31	0,273	0,074	-0,165	56	0,282	0,079	-0,096	81	0,314	0,099	-0,178
7	0,459	0,210	-0,040	32	0,317	0,100	-0,130	57	0,239	0,057	-0,251	82	0,166	0,028	-0,184
8	0,390	0,152	-0,022	33	0,232	0,054	-0,169	58	0,270	0,073	-0,144	83	0,302	0,091	-0,121
9	0,319	0,102	-0,139	34	0,282	0,079	-0,175	59	0,300	0,090	-0,151	84	0,347	0,120	-0,224
10	0,323	0,104	-0,177	35	0,169	0,029	-0,194	60	0,296	0,088	-0,201	85	0,377	0,142	-0,066
11	0,176	0,031	-0,235	36	0,166	0,028	-0,195	61	0,283	0,080	-0,107	86	0,256	0,066	-0,168
12	0,293	0,086	-0,145	37	0,174	0,030	-0,253	62	0,336	0,113	-0,086	87	0,318	0,101	-0,225
13	0,488	0,238	0,104	38	0,403	0,162	-0,072	63	0,404	0,164	-0,007	88	0,398	0,158	-0,057
14	0,377	0,142	-0,052	39	0,243	0,059	-0,145	64	0,442	0,195	0,003	89	0,253	0,064	-0,139
15	0,317	0,101	-0,119	40	0,458	0,210	-0,025	65	0,317	0,101	-0,109	90	0,458	0,210	0,004
16	0,395	0,156	-0,086	41	0,261	0,068	-0,197	66	0,348	0,121	-0,160	91	0,396	0,157	-0,068
17	0,245	0,060	-0,268	42	0,166	0,028	-0,230	67	0,164	0,027	-0,228	92	0,430	0,185	-0,070
18	0,264	0,070	-0,150	43	0,231	0,053	-0,193	68	0,263	0,069	-0,299	93	0,256	0,065	-0,150
19	0,246	0,060	-0,154	44	0,201	0,041	-0,235	69	0,210	0,044	-0,202	94	0,279	0,078	-0,224
20	0,305	0,093	-0,138	45	0,271	0,073	-0,122	70	0,285	0,081	-0,104	95	0,194	0,038	-0,191
21	0,154	0,024	-0,179	46	0,225	0,051	-0,238	71	0,190	0,036	-0,287	96	0,260	0,068	-0,122
22	0,269	0,073	-0,257	47	0,336	0,113	-0,075	72	0,349	0,122	-0,080	97	0,204	0,042	-0,268
23	0,151	0,023	-0,225	48	0,373	0,139	-0,071	73	0,285	0,081	-0,142	98	0,324	0,105	-0,182
24	0,286	0,082	-0,149	49	0,261	0,068	-0,171	74	0,210	0,044	-0,192	99	0,279	0,078	-0,261
25	0,142	0,020	-0,313	50	0,364	0,132	-0,088	75	0,219	0,048	-0,152	100	0,120	0,014	-0,217
Average				R				R ²				R ² _{CV}			
				0,282				0,087				-0,155			
												cR _p ²			
												0,557			




Fig. 5. Williams plot of standardized residual versus leverage for the MLR model (With: $h^* = 0.260$ and residual limits = ± 2.5); Train samples in black colour and test samples in red colour).

leverage threshold values ($h^* = 0.260$) were plotted. Any new value of predicted pEC_{50} data must be considered reliable only for those compounds that fall within this AD on which the model was constructed.

From the Fig. 5, it is obvious that all the compounds have a standard deviation into the $\pm x$ interval ($x = 2.5$) and there is two responses outliers both in training set and no response outside in test set. These outliers (compounds 23 and 25) have a higher leverage which is greater than h^* value of 0.260. These erroneous predictions could probably be attributed to the structural of these outsiders (Fig. 6); maybe the selected




Fig. 6. Chemical structures of the outsiders compounds.

descriptors do not pay much attention to these substructures or their mechanism of action may be different. The predictions of these two compounds are extrapolations of the model, but fortunately they are all “good leverage” chemicals.

The results obtained by MLR are very sufficient to conclude the performance of the models. Consequently, we can design new compounds with improved values of activity than the studied compounds using this model.

Taking into account the above results, we added suitable substitutions and then we moved to calculate their activities using the proposed models Eq. (1). Therefore, the suggested model will reduce the time and cost of synthesis as well as the determination of the anti-HAT activity for the 2-phenylimidazopyridines derivatives.

According to the above discussions, the MLR model could be applied to other 2-phenylimidazopyridines derivatives accordingly to Table 1 and could add further knowledge in the improvement of new way in anti-HAT drug research. If we develop a new compound with better values than the existing ones, it may give rise to the development of more active compounds than those currently in use.

In this way, we carried out structural modification starting from compounds having the highest pEC₅₀ values as template (38, 41, 44, and 49). The structures of the designed compounds and their parameter values calculated by the same methods, as well as the pEC₅₀ values theoretically predicted by the MLR model are listed in Table 7.

Table 7. Values of descriptors, calculated anti-HAT activity pEC₅₀ and leverages (h) for the new designed compounds (derivatives of the skeleton (C) of the Fig. 1).

	Designed compounds	E _{LUMO}	MW	NHD	logP	pEC ₅₀	leverage
X ₁	R ₁ =COOH; R ₂ =COOH	-2.129	421.095	5	2.773	8.837	0.436
X ₂	R ₁ =NO ₂ ; R ₂ = NO ₂	-2.658	427.117	7	0.745	9.125	1.596
X ₃	R ₁ =NH ₂ ; R ₂ = p-PhNH ₂	-1.680	363.138	5	1.796	8.669	0.588
X ₄	R ₁ =N-pyrrolidinyl; R ₂ = m-PhNO ₂	-1.780	446.163	4	4.048	8.919	0.170
X ₅	R ₁ =N-pyrrolidinyl; R ₂ = p-PhNO ₂	-1.934	446.163	4	4.048	8.735	0.145
X ₆	R ₁ =N-pyrrolidinyl; R ₂ = p-PhOH	-1.627	418.168	4	3.733	8.698	0.191
X ₇	R ₁ =N-pyrrolidinyl; R ₂ = m,p-Ph(OH) ₂	-1.650	434.163	3	3.327	8.834	0.208
X ₈	R ₁ = N-pyrrolidinyl; R ₂ =3-thio-2,4-dihydroxyphenyl	-1.493	440.120	5	3.926	9.498	0.395
X ₉	R ₁ = N-pyrrolidinyl; R ₂ =3-methyl-4-hydroxyphenyl	-1.600	432.184	4	4.182	8.817	0.176
X ₁₀	R ₁ = N-pyrrolidinyl; R ₂ =3-methyl-6-hydroxyphenyl	-1.543	432.184	4	3.932	8.984	0.214
X ₁₁	R ₁ = N-pyrrolidinyl; R ₂ =3-methyl-5-hydroxyphenyl	-1.637	432.184	4	4.232	8.753	0.164

4. Conclusion

The results of the QSAR analysis suggest that derivatives of 2-phenylimidazopyridines with the following structural feature may exhibit great anti-HAT activity by increasing molecular size and substitute the 2-phenylimidazopyridines derivatives with polar, ionic, stronger accepting electron ability group and heteroatoms attached to one or more hydrogen atoms.

According to developed model, the most important findings of this research are that we have designed and suggest some new compounds with possible great activities. Consequently, the proposed models can be used in anti-HAT drug research for the 2-phenylimidazopyridines derivatives. These results encourage the collaboration between theoretical researchers and pharmacologists, academic or industrial, because the last ones many times are groping new drugs.

Declarations

Author contribution statement

Samir Chtita: Analyzed and interpreted the data; Wrote the paper.

Mounir Ghamali, Abdellah Ousaa, Assia Belhassan, Abdelali Idrissi Taourati: Analyzed and interpreted the data.

Adnane Aouidate: Conceived and designed the experiments.

Vijay Hariram Masand: Contributed reagents, materials, analysis tools or data; Wrote the paper.

Mohammed Bouachrine: Contributed reagents, materials, analysis tools or data.

Tahar Lakhlif: Conceived and designed the experiments.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

Acknowledgements

We are grateful to the “Association Marocaine des Chimistes Théoriciens” (AMCT) for its pertinent help concerning the programs.

References

- [1] P.J. Hotez, A. Fenwick, L. Savioli, D.H. Molyneux, Rescuing the bottom billion through control of neglected tropical diseases, *Lancet* 373 (2009) 1570–1575.
- [2] K. Chibale, New developments in antiinfectives research for tropical infectious diseases, *Bioorg. Med. Chem.* 23 (16) (2015) 5085–5086.
- [3] M. Njoroge, N.M. Njuguna, P. Mutai, D.S.B. Ongarora, P.W. Smith, K. Chibale, Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis, *Chem. Rev.* 114 (2014) 11138–11163.
- [4] www.who.int/mediacentre/factsheets/fs259/en/. (Accessed 27 February 2019).
- [5] D. Steverding, The history of African trypanosomiasis, *Parasites Vectors* 3–3 (2008) 1–8.
- [6] R. Brun, J. Blum, F. Chappuis, C. Burri, Human African trypanosomiasis, *Lancet* 375 (2010) 148–159.
- [7] R. Brun, R. Don, R.T. Jacobs, M.Z. Wang, M.P. Barrett, Development of novel drugs for human African trypanosomiasis, *Future Microbiol.* 6 (2011) 677–691.
- [8] P.G. Kennedy, Clinical features, diagnosis, and treatment of human African trypanosomiasis, *Lancet Neurol.* 12 (2) (2013) 186–194.
- [9] World Health organization WHO, Mapping the Risk of Human African Trypanosomiasis, 2016. www.who.int/trypanosomiasis_african/country/risk_AFRO/en. (Accessed 27 February 2019).
- [10] Trypanosomiasis, Human African (Sleeping Sickness), 2016. www.who.int/mediacentre/factsheets/fs259/en/. (Accessed 27 February 2019).
- [11] J. Rodgers, Human African trypanosomiasis, chemotherapy and CNS disease, *J. Neuroimmunol.* 211 (2009) 16–22.
- [12] F. Olmo, C. Rotger, I. Ramirez-Macias, L. Martinez, C. Marin, L. Carreras, K. Urbanova, M. Vega, G. Chaves-Lemaur, A. Sampedro, M.J. Rosales, M. Sanchez-Moreno, A. Costa, Synthesis and biological evaluation of N,N'-

- squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease, *J. Med. Chem.* 57 (3) (2014) 987–999.
- [13] J.J. Nogueira Silva, W.R. Pavanelli, F.R. Salazar Gutierrez, F.C. Alves Lima, A.B. Ferreira da Silva, J. Santana Silva, D. Wagner Franco, Complexation of the anti-trypanosoma cruzi drug benznidazole improves solubility and efficacy, *J. Med. Chem.* 51 (14) (2008) 4104–4114.
- [14] S. Garcia, C.O. Ramos, J.F.V. Senra, F. Vilas-Boas, M.M. Rodrigues, A.C. Campos-de-Carvalho, R. Ribeiro-dos- Santos, M.B.P. Soares, Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations, *Antimicrob. Agents Chemother.* 49 (4) (2005) 1521–1528.
- [15] S. Russell, R. Rahmani, A.J. Jones, H.L. Newson, K. Neilde, I. Cotillo, M. Rahmani Khajouei, L. Ferrins, S. Qureishi, N. Nguyen, M.S. Martinez-Martinez, D.F. Weaver, M. Kaiser, J. Riley, J. Thomas, M. De Rycker, K.D. Read, G.R. Flematti, E. Ryan, S. Tanghe, A. Rodriguez, S.A. Charman, A. Kessler, V.M. Avery, J.B. Baell, M.J. Piggott, Hit-to-lead optimization of a novel class of potent, broad-spectrum trypanosomacides, *J. Med. Chem.* 59 (21) (2016) 9686–9720.
- [16] J.A. Urbina, R. Docampo, Specific chemotherapy of Chagas disease: controversies and advances, *Trends Parasitol.* 19 (11) (2003) 495–501.
- [17] J.A. Castro, M.M. de Mecca, L.C. Bartel, Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis), *Hum. Exp. Toxicol.* 25 (8) (2006) 471–479.
- [18] H.B. Tatipaka, J.R. Gillespie, A.K. Chatterjee, N.R. Norcross, M.A. Hulverson, R.M. Ranade, P. Nagendar, S.A. Creason, J. McQueen, N.A. Duster, A. Nagle, F. Supek, V. Molteni, T. Wenzler, R. Brun, R. Glynne, F.S. Buckner, M.H. Gelb, Substituted 2-henylimidazopyridines: a new class of drug leads for human African trypanosomiasis, *J. Med. Chem.* 57 (2014) 828–835.
- [19] S. Chtita, M. Ghamali, M. Larif, R. Hmamouchi, M. Bouachrine, T. Lakhli, Quantitative structure–activity relationship studies of anticancer activity for Isatin (1H-indole-2,3-dione) derivatives based on density functional theory with electronic and topological descriptors, *Int. J. Quant. Struct. Prop. Relatsh.* 2 (2) (2017) 90–115.
- [20] S. Chtita, M. Ghamali, R. Hmamouchi, B. Elidrissi, M. Bourass, M. Larif, M. Bouachrine, T. Lakhli, Investigation of antileishmanial activities of acridines derivatives against promastigotes and amastigotes form of parasites

using quantitative structure activity relationship analysis, *Adv. Phys. Chem.* (2016) 1–16.

- [21] Adamo, Baron, Parac & Grimme Gaussian 03 2003, 2000.
- [22] ChemBioOffice, PerkinElmer Informatics, 2010. www.cambridgesoft.com. (Accessed 27 February 2019).
- [23] XLSTAT, Software, XLSTAT Company, 2013. www.xlstat.com. (Accessed 27 February 2019).
- [24] J.C. Dearden, M.T.D. Cronin, K.L.E. Kaiser, How not to develop a QSAR/ QSPR, *SAR QSAR Environ. Res.* 20 (3-4) (2009) 241–266.
- [25] J. Henseler, C. Ringle, R. Sinkovics, The use of partial least squares path modeling in international marketing, *Adv. Int. Market.* 20 (2009) 277–320.
- [26] J.F. Hair, C.M. Ringle, Sarstedt, Partial least squares structural equation modeling: rigorous applications, better results and higher acceptance, *Long. Range Plan.* 46 (2013) 1–12.
- [27] J.F. Hair, C.M. Ringle, M. Sarstedt, PLS-SEM: indeed a silver bullet, *J. Mark. Theory Pract.* 19 (2) (2011) 139–152.
- [28] W.G. Zikmund, *Business Research Methods*, sixth ed., Harcourt College Publishers, Fort Worth, 2000.
- [29] D.S. Moore, W.I. Notz, M.A. Flinger, *The Basic Practice of Statistics*, sixth ed., W. H. Freeman and Company, New York, NY, 2013.
- [30] E.L. Lehmann, G. Casella, *Theory of Point Estimation*, second ed., Springer, New York, 1998.
- [31] R.M. O'Brien, A caution regarding rules of thumb for variance inflation factors, *Qual. Quantity* 41 (2007) 673–690.
- [32] K. Roy, On some aspects of validation of predictive quantitative structure–activity relationship models, *Expert Opin. Drug Discov.* 2 (12) (2007).
- [33] D.W. Osten, Selection of optimal regression models via cross validation, *J. Chemom.* 2 (1998) 39–48.
- [34] S. Ekins, G. Bravi, S. Binkley, J.S. Gillespie, B.J. Ring, J.H. Wikel, S.A. Wrighton, Three and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors, *Drug Metab. Dispos.* 28 (2000) 994–1002.

- [35] OECD Guidance Document on the Validation of QSAR Models, Organization for Economic Co-operation & Development, Paris, 2007.
- [36] L. Eriksson, J. Jaworska, A.P. Worth, M.T.D. Cronin, R.M. McDowell, P. Gramatica, Methods for reliability & uncertainty assessment & for applicability evaluations of classification & regression-based QSARs, *Environ. Health Persp.* 111 (10) (2003) 1361–1375.
- [37] P. Gramatica, Principles of QSAR models validation: internal & external, *QSAR Comb. Sci.* 26 (5) (2007) 694–701.
- [38] G.E. Batista, D.F. Silva, How K-Nearest Neighbor Parameters Affect its Performance, Argentine Symposium on Artificial Intelligence, Instituto de Ciencias Matemáticas de Computación, Sao Carlos — SP — Brasil, 2009, pp. 1–12.
- [39] T.I. Netzeva, A.P. Worth, T. Aldenberg, R. Benigni, M.T.D. Cronin, P. Gramatica, J.S. Jaworska, S. Kahn, G. Klopman, C.A. Marchant, G. Myatt, N. Nikolova-Jeliazkova, G.Y. Patlewicz, R. Perkins, D.W. Roberts, T.W. Schultz, D.T. Stanton, J.J.M. Van De Sandt, W. Tong, G. Veith, C. Yang, Current status of methods for defining the applicability domain of (quantitative) structure–activity relationships, *Altern. Lab. Anim.* 33 (2) (2005) 155–173.
- [40] J.C. Dearden, The history & development of QSARs, *Int. J. Quantit. Struct. Prop. Relatsh.* 1 (1) (2016).
- [41] S. Zhang, A. Golbraikh, S. Oloff, H. Kohn, A. Tropsha, A novel Automated lazy learning QSAR (ALL-QSAR) Approach: method development, Applications, and virtual screening of chemical databases using validated ALL-QSAR models, *J. Chem. Inf. Model.* 46 (5) (2006) 1984–1995.
- [42] K. Roy, S. Kar, R. Narayan Das, A Primer on QSAR/QSPR Modeling: Fundamental Concepts, Theoretical and Computational Chemistry, 2015.
- [43] J. Holder, Ye. Lin, E.J. David, C. Cecil, C.C. Chappelow, A quantum-mechanical QSAR model to predict the refractive index of polymer matrices, *QSAR Comb. Sci.* 25 (10) (2006) 905–911.
- [44] A.K. Srivastava, N. Shukla, A. Pandey, A. Srivastava, QSAR based modeling on a series of α -hydroxy amides as a novel class of bradykinin B1 selective antagonists, *Journal of Saudi Chemical Society* 15 (3) (2011) 215–220.
- [45] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug

- discovery and development settings, *Adv. Drug Deliv. Rev.* 6 (1–3) (1997) 3–25.
- [46] S.C. Moldoveanu, V. David, Chapter 13 - Solvents, Buffers, and Additives Used in the Mobile Phase, *Selection of the HPLC Method in Chemical Analysis*, 2017, pp. 393–450.
- [47] J. Isac-García, J.A. Dobado, F.G. Calvo-Flores, H. Martínez-García, Chapter 5 - Determining Physical and Spectroscopic Properties, *Experimental Organic Chemistry*, Academic Press, 2016, pp. 145–175.
- [48] C. Hansch, C. Selassie, Quantitative structure–activity relationship – a historical perspective and the future, in: *Reference Module in Chemistry, Molecular Sciences and Chemical Engineering, Comprehensive Medicinal Chemistry II*, 4, 2007, pp. 43–63.
- [49] A.A. Oliferenko, P.V. Oliferenko, J.G. Huddleston, R.D. Rogers, V.A. Palyulin, N.S. Zefirov, A.R. Katritzky, Theoretical scales of hydrogen bond Acidity and basicity for Application in QSAR/QSPR studies and drug design, *J. Chem. Inf. Comput. Sci.* 44 (3) (2004) 1042–1055.
- [50] K. Fukui, Role of frontier orbitals in chemical reactions, *Science* 218 (1982) 747–754.
- [51] S. Chtita, M. Larif, M. Ghamali, M. Bouachrine, T. Lakhli, Quantitative structure–activity relationship studies of dibenzo[a,d]cycloalkenimine derivatives for non-competitive antagonists of N-methyl-d-aspartate based on density functional theory with electronic and topological descriptors, *J. Taibah Univ. Sci.* 9 (2) (2015) 143–154.
- [52] V.H. Masand, N.N.E. El-Sayed, D.T. Mahajan, A.G. Mercader, A.M. Alafeefy, I.G. Shibi, QSAR modeling for anti-human African trypanosomiasis activity of substituted 2-Phenylimidazopyridines, *J. Mol. Struct.* 1130 (2017) 711–718.
- [53] K. Roy, R.N. Das, P. Ambure, R.B. Aher, Be aware of error measures. Further studies on validation of predictive QSAR models, *Chemometr. Intell. Lab. Syst.* 152 (2016) 18–33.